In a retrospective cohort study, ustekinumab and guselkumab show trends toward lower risk for herpes zoster in patients with ...

The psoriasis market is estimated at $30 Billion by 2030 and has shifted significantly to oral drugs Ramat Gan, Israel, March ...

Apremilast improves disease severity and patient-reported outcomes among adults with psoriasis, regardless of genital involvement.

Adults taking the novel once-daily oral pill for plaque psoriasis have significantly higher rates of clear or almost clear ...

“ Psoriasis is an inflammatory skin disorder, due to an overactive immune system,” said Dr. Omar Noor. “That over active immune system produces inflammation in the skin that causes the skin to develop ...

Biologics targeting interleukin-12, -23, and -17 were associated with a lower rate of serious infections among older adults ...

A recent review highlights how the Mediterranean diet can reduce inflammation and improve outcomes for chronic skin ...

Announcing a new publication for Acta Materia Medica journal. Phosphodiesterase-4 (PDE4), a member of the phosphodiesterase ...

Can-Fite BioPharma initiates pivotal Phase 3 study for psoriasis treatment using oral drug Piclidenoson, targeting moderate to severe cases. Can-Fite BioPharma Ltd. announced the initiation of a ...

Patients with skin disease adhering to a proper diet may experience better treatment responses and a reduced risk of adverse ...

Medicare coverage for psoriasis drugs depends on the type of Medicare plan you have and the drug your doctor prescribes. But if your doctor considers a drug medically necessary, Medicare may cover it.

The psoriasis market is estimated at $30 Billion by 2030 and has shifted significantly to oral drugs Ramat Gan, Israel, March 24, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) ...